List of Tables
    Table 1. Targeted Drugs for NSCLC Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
    Table 2. Targeted Drugs for NSCLC Market Trends
    Table 3. Targeted Drugs for NSCLC Market Drivers
    Table 4. Targeted Drugs for NSCLC Market Challenges
    Table 5. Targeted Drugs for NSCLC Market Restraints
    Table 6. Global Targeted Drugs for NSCLC Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Targeted Drugs for NSCLC Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Targeted Drugs for NSCLC Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Targeted Drugs for NSCLC Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Targeted Drugs for NSCLC Companies in Global Market, Ranking by Revenue (2021)
    Table 11. Global Targeted Drugs for NSCLC Revenue by Player, (US$ Million), 2017-2022
    Table 12. Global Targeted Drugs for NSCLC Revenue Share by Player, 2017-2022
    Table 13. Global Targeted Drugs for NSCLC Companies Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Targeted Drugs for NSCLC by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for NSCLC as of 2021)
    Table 15. Top Players of Targeted Drugs for NSCLC in Global Market, Headquarters and Area Served
    Table 16. Companies Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million) Type
    Table 17. Date of International Companies Enter into Targeted Drugs for NSCLC Market
    Table 18. Companies Mergers & Acquisitions, Expansion Plans
    Table 19. Top Targeted Drugs for NSCLC Players in United States Market, Ranking by Revenue (2021)
    Table 20. United States Targeted Drugs for NSCLC Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 21. United States Targeted Drugs for NSCLC Revenue Share by Players, 2020, 2021 & 2022
    Table 22. Global Targeted Drugs for NSCLC Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 23. Global Targeted Drugs for NSCLC Market Size by Region (2017-2022) & (US$ Million)
    Table 24. Global Targeted Drugs for NSCLC Market Size Forecast by Region (2023-2028) & (US$ Million)
    Table 25. North America Targeted Drugs for NSCLC Sales in Value by Country (2017-2028) & (US$ Million)
    Table 26. Asia Pacific Targeted Drugs for NSCLC Sales in Value by Region (2017-2028) & (US$ Million)
    Table 27. Europe Targeted Drugs for NSCLC Sales in Value by Country (2017-2028) & (US$ Million)
    Table 28. Latin Americaa Targeted Drugs for NSCLC Sales in Value by Country (2017-2028) & (US$ Million)
    Table 29. Middle East and Africa Targeted Drugs for NSCLC Sales in Value by Country (2017-2028) & (US$ Million)
    Table 30. Allergan Company Details
    Table 31. Allergan Business Overview
    Table 32. Allergan Targeted Drugs for NSCLC Product
    Table 33. Allergan Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 34. Allergan Recent Development
    Table 35. Amgen Company Details
    Table 36. Amgen Business Overview
    Table 37. Amgen Targeted Drugs for NSCLC Product
    Table 38. Amgen Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 39. Amgen Recent Development
    Table 40. ARIAD Pharmaceuticals (Takeda) Company Details
    Table 41. ARIAD Pharmaceuticals (Takeda) Business Overview
    Table 42. ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Product
    Table 43. ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 44. ARIAD Pharmaceuticals (Takeda) Recent Development
    Table 45. Beacon Pharma Limited Company Details
    Table 46. Beacon Pharma Limited Business Overview
    Table 47. Beacon Pharma Limited Targeted Drugs for NSCLC Product
    Table 48. Beacon Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 49. Beacon Pharma Limited Recent Development
    Table 50. BeiGene Company Details
    Table 51. BeiGene Business Overview
    Table 52. BeiGene Targeted Drugs for NSCLC Product
    Table 53. BeiGene Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 54. BeiGene Recent Development
    Table 55. Biocon Company Details
    Table 56. Biocon Business Overview
    Table 57. Biocon Targeted Drugs for NSCLC Product
    Table 58. Biocon Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 59. Biocon Recent Development
    Table 60. Boehringer-Ingelheim Company Details
    Table 61. Boehringer-Ingelheim Business Overview
    Table 62. Boehringer-Ingelheim Targeted Drugs for NSCLC Product
    Table 63. Boehringer-Ingelheim Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 64. Boehringer-Ingelheim Recent Development
    Table 65. Celgene Corporation Company Details
    Table 66. Celgene Corporation Business Overview
    Table 67. Celgene Corporation Targeted Drugs for NSCLC Product
    Table 68. Celgene Corporation Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 69. Celgene Corporation Recent Development
    Table 70. Drug International Limted Company Details
    Table 71. Drug International Limted Business Overview
    Table 72. Drug International Limted Targeted Drugs for NSCLC Product
    Table 73. Drug International Limted Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 74. Drug International Limted Recent Development
    Table 75. Fujifilm Kyowa Kirin Biologics Company Details
    Table 76. Fujifilm Kyowa Kirin Biologics Business Overview
    Table 77. Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Product
    Table 78. Fujifilm Kyowa Kirin Biologics Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 79. Fujifilm Kyowa Kirin Biologics Recent Development
    Table 80. Genvio Pharma Limited Company Details
    Table 81. Genvio Pharma Limited Business Overview
    Table 82. Genvio Pharma Limited Targeted Drugs for NSCLC Product
    Table 83. Genvio Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 84. Genvio Pharma Limited Recent Development
    Table 85. Hetero Drugs Company Details
    Table 86. Hetero Drugs Business Overview
    Table 87. Hetero Drugs Targeted Drugs for NSCLC Product
    Table 88. Hetero Drugs Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 89. Hetero Drugs Recent Development
    Table 90. ImClone Systems ‎(Eli Lilly) Company Details
    Table 91. ImClone Systems ‎(Eli Lilly) Business Overview
    Table 92. ImClone Systems ‎(Eli Lilly) Targeted Drugs for NSCLC Product
    Table 93. ImClone Systems ‎(Eli Lilly) Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 94. ImClone Systems ‎(Eli Lilly) Recent Development
    Table 95. Incepta Pharmaceuticals Company Details
    Table 96. Incepta Pharmaceuticals Business Overview
    Table 97. Incepta Pharmaceuticals Targeted Drugs for NSCLC Product
    Table 98. Incepta Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 99. Incepta Pharmaceuticals Recent Development
    Table 100. Mylan Company Details
    Table 101. Mylan Business Overview
    Table 102. Mylan Targeted Drugs for NSCLC Product
    Table 103. Mylan Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 104. Mylan Recent Development
    Table 105. Novartis Company Details
    Table 106. Novartis Business Overview
    Table 107. Novartis Targeted Drugs for NSCLC Product
    Table 108. Novartis Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 109. Novartis Recent Development
    Table 110. Pfizer Company Details
    Table 111. Pfizer Business Overview
    Table 112. Pfizer Targeted Drugs for NSCLC Product
    Table 113. Pfizer Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 114. Pfizer Recent Development
    Table 115. Reliance Lifesciences Company Details
    Table 116. Reliance Lifesciences Business Overview
    Table 117. Reliance Lifesciences Targeted Drugs for NSCLC Product
    Table 118. Reliance Lifesciences Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 119. Reliance Lifesciences Recent Development
    Table 120. Roche Company Details
    Table 121. Roche Business Overview
    Table 122. Roche Targeted Drugs for NSCLC Product
    Table 123. Roche Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 124. Roche Recent Development
    Table 125. AstraZeneca Company Details
    Table 126. AstraZeneca Business Overview
    Table 127. AstraZeneca Targeted Drugs for NSCLC Product
    Table 128. AstraZeneca Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 129. AstraZeneca Recent Development
    Table 130. Cipla Company Details
    Table 131. Cipla Business Overview
    Table 132. Cipla Targeted Drugs for NSCLC Product
    Table 133. Cipla Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 134. Cipla Recent Development
    Table 135. Teva Company Details
    Table 136. Teva Business Overview
    Table 137. Teva Targeted Drugs for NSCLC Product
    Table 138. Teva Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 139. Teva Recent Development
    Table 140. OSI Pharmaceuticals Company Details
    Table 141. OSI Pharmaceuticals Business Overview
    Table 142. OSI Pharmaceuticals Targeted Drugs for NSCLC Product
    Table 143. OSI Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 144. OSI Pharmaceuticals Recent Development
    Table 145. Glenmark Pharmaceuticals Company Details
    Table 146. Glenmark Pharmaceuticals Business Overview
    Table 147. Glenmark Pharmaceuticals Targeted Drugs for NSCLC Product
    Table 148. Glenmark Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 149. Glenmark Pharmaceuticals Recent Development
    Table 150. Natco Pharma Company Details
    Table 151. Natco Pharma Business Overview
    Table 152. Natco Pharma Targeted Drugs for NSCLC Product
    Table 153. Natco Pharma Revenue in Targeted Drugs for NSCLC Business (2017-2022) & (US$ Million)
    Table 154. Natco Pharma Recent Development
    Table 155. Research Programs/Design for This Report
    Table 156. Key Data Information from Secondary Sources
    Table 157. Key Data Information from Primary Sources
List of Figures
    Figure 1. Targeted Drugs for NSCLC Product Picture
    Figure 2. Global Targeted Drugs for NSCLC Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Targeted Drugs for NSCLC Market Size 2017-2028 (US$ Million)
    Figure 4. United States Targeted Drugs for NSCLC Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 5. United States Targeted Drugs for NSCLC Market Size 2017-2028 (US$ Million)
    Figure 6. United States Targeted Drugs for NSCLC Market Share in Global 2017-2028
    Figure 7. Targeted Drugs for NSCLC Report Years Considered
    Figure 8. Product Picture of Target EGFR
    Figure 9. Product Picture of Target ALK
    Figure 10. Product Picture of Target HER2
    Figure 11. Product Picture of Target ROS1
    Figure 12. Product Picture of Target BRAF
    Figure 13. Product Picture of Target MEK
    Figure 14. Product Picture of Target VEGFR2
    Figure 15. Product Picture of Target VEGF
    Figure 16. Product Picture of Target MET
    Figure 17. Global Targeted Drugs for NSCLC Market Share by Type in 2022 & 2028
    Figure 18. Global Targeted Drugs for NSCLC Market Size by Type (2017-2028) & (US$ Million)
    Figure 19. Global Targeted Drugs for NSCLC Market Share by Type (2017-2028)
    Figure 20. United States Targeted Drugs for NSCLC Market Share by Type in 2022 & 2028
    Figure 21. United States Targeted Drugs for NSCLC Market Size by Type (2017-2028) & (US$ Million)
    Figure 22. United States Targeted Drugs for NSCLC Market Share by Type (2017-2028)
    Figure 23. Product Picture of Squamous Cell Carcinoma of NSCLC
    Figure 24. Product Picture of Adenocarcinoma of NSCLC
    Figure 25. Product Picture of Large Cell Carcinoma of NSCLC
    Figure 26. Global Targeted Drugs for NSCLC Market Share by Application in 2022 & 2028
    Figure 27. Global Targeted Drugs for NSCLC Market Size by Application (2017-2028) & (US$ Million)
    Figure 28. Global Targeted Drugs for NSCLC Market Share by Application (2017-2028)
    Figure 29. United States Targeted Drugs for NSCLC Market Share by Application in 2022 & 2028
    Figure 30. United States Targeted Drugs for NSCLC Market Size by Application (2017-2028) & (US$ Million)
    Figure 31. United States Targeted Drugs for NSCLC Market Share by Application (2017-2028)
    Figure 32. North America Targeted Drugs for NSCLC Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 33. U.S. Targeted Drugs for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 34. Canada Targeted Drugs for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 35. Europe Targeted Drugs for NSCLC Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 36. Germany Targeted Drugs for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 37. France Targeted Drugs for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 38. U.K. Targeted Drugs for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 39. Italy Targeted Drugs for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 40. Russia Targeted Drugs for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 41. Asia-Pacific Targeted Drugs for NSCLC Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 42. China Targeted Drugs for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 43. Japan Targeted Drugs for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 44. South Korea Targeted Drugs for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 45. India Targeted Drugs for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 46. Australia Targeted Drugs for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 47. Taiwan Targeted Drugs for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 48. Indonesia Targeted Drugs for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 49. Thailand Targeted Drugs for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Malaysia Targeted Drugs for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 51. Philippines Targeted Drugs for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 52. Latin America Targeted Drugs for NSCLC Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 53. Mexico Targeted Drugs for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 54. Brazil Targeted Drugs for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 55. Argentina Targeted Drugs for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 56. Middle East & Africa Targeted Drugs for NSCLC Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 57. Turkey Targeted Drugs for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 58. Saudi Arabia Targeted Drugs for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 59. U.A.E Targeted Drugs for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 60. Allergan Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 61. Amgen Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 62. ARIAD Pharmaceuticals (Takeda) Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 63. Beacon Pharma Limited Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 64. BeiGene Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 65. Biocon Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 66. Boehringer-Ingelheim Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 67. Celgene Corporation Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 68. Drug International Limted Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 69. Fujifilm Kyowa Kirin Biologics Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 70. Genvio Pharma Limited Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 71. Hetero Drugs Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 72. ImClone Systems ‎(Eli Lilly) Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 73. Incepta Pharmaceuticals Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 74. Mylan Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 75. Novartis Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 76. Pfizer Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 77. Reliance Lifesciences Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 78. Roche Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 79. AstraZeneca Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 80. Cipla Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 81. Teva Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 82. OSI Pharmaceuticals Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 83. Glenmark Pharmaceuticals Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 84. Natco Pharma Revenue Growth Rate in Targeted Drugs for NSCLC Business (2017-2022)
    Figure 85. Bottom-up and Top-down Approaches for This Report
    Figure 86. Data Triangulation
    Figure 87. Key Executives Interviewed